Posted by Michael Wonder on 17 Jan 2019
Aeterna Zentaris receives European marketing clearance for macimorelin
16 January 2018 - Aeterna Zentaris announced that the EMA has granted marketing authorisation for macimorelin, an orally available ghrelin agonist, for diagnosis of adult growth hormone deficiency.
The approval came following the CHMP positive opinion of macimorelin on 15 November 2018.
